8-K: DermTech Reports Improved Fourth-Quarter 2023 Financial Results with Focus on Revenue Growth and Cost Reduction

DermTech's Q4 2023 results show a significant increase in test revenue and average selling price, alongside reduced operating expenses, positioning the company for a longer cash runway.

Summary

• DermTech reported its fourth-quarter 2023 financial results, showing a 38% increase in test revenue compared to the same period in 2022, reaching $3.7 million.
• Total revenue for the quarter was $3.9 million, a 31% increase year-over-year, primarily driven by higher test revenue.
• The average selling price (ASP) for the DermTech Melanoma Test (DMT) increased by 55% year-over-year.
• Billable sample volume decreased by 11% to approximately 15,580 compared to the fourth quarter of 2022.
• The company achieved a test gross margin of 7%, a significant improvement from a negative 22% in the fourth quarter of 2022.
• Operating expenses saw substantial reductions, with sales and marketing expenses down 38%, research and development down 34%, and general and administrative expenses down 14% compared to Q4 2022.
• Net loss for the quarter was $19.1 million, or ($0.56) per share, compared to a net loss of $28.2 million, or ($0.93) per share, in the fourth quarter of 2022.
• DermTech estimates its cash runway extends into the first quarter of 2025.
• The company plans to achieve approximately $40 million in annualized total operating expense reductions compared to 2022.

Sentiment

Score: 7

Explanation: The document shows positive trends in revenue growth, gross margin improvement, and cost reduction, but the company is still operating at a loss and faces risks related to reimbursement and market adoption. The sentiment is cautiously optimistic.

Positives

• The company has significantly increased its average selling price for the DermTech Melanoma Test.
• Test revenue and total revenue have shown strong year-over-year growth.
• Gross margins have improved substantially, moving from negative to positive.
• Operating expenses have been significantly reduced across all categories.
• The company has extended its estimated cash runway into the first quarter of 2025.
• DermTech has increased its proportion of Medicare billable samples.

Negatives

• Billable sample volume decreased by 11% compared to the fourth quarter of 2022.
• The company reported a net loss of $19.1 million for the quarter, although this is an improvement from the previous year.
• Cost of test revenue increased due to higher infrastructure costs related to the new facility.

Risks

• The company's ability to obtain additional capital when needed is a risk.
• Reimbursement of DermTech's tests by government and commercial payers is a key factor.
• Market adoption and demand for DermTech's products and services are subject to economic and competitive factors.
• The company's ability to continue as a going concern is a risk factor.
• Legal proceedings could impact the company.
• Changes in applicable laws or regulations could affect the business.

Future Outlook

DermTech believes it has sufficient cash resources to fund its planned operations into the first quarter of 2025 and will continue emphasizing average selling price and revenue growth in 2024.

Management Comments

• We reported sustained improvement in many of our key performance indicators during the second half of last year and will continue emphasizing average selling price (ASP) and revenue growth in 2024, said Bret Christensen, CEO, DermTech.
• We've aligned our commercial effort with the aim to maximize revenue by focusing on existing customers and reimbursed tests.
• We've also delivered on our commitment to find additional operating efficiencies and being diligent with the allocation of our resources.
• We now plan to achieve approximately $40 million in annualized total operating expense reductions compared to 2022, as a result of our restructuring actions during the last several months.
• We have a great technology that can significantly enhance the standard of care for evaluating melanoma, while also lowering healthcare costs and providing a better patient experience.

Industry Context

DermTech's focus on precision dermatology and non-invasive testing aligns with the broader trend in healthcare towards personalized medicine and less invasive diagnostic procedures. The company's efforts to increase ASP and reduce operating costs are crucial for long-term sustainability in a competitive market.

Comparison to Industry Standards

• DermTech's 55% increase in ASP for its melanoma test is a significant achievement, suggesting strong pricing power or a shift in payer mix, which is favorable compared to other diagnostic companies.
• The improvement in gross margin from negative 22% to positive 7% indicates a substantial improvement in operational efficiency and cost management, which is a key metric for companies in the diagnostics sector.
• The reduction in operating expenses by 38% in sales and marketing, 34% in R&D, and 14% in G&A demonstrates a strong commitment to cost control, which is essential for companies in the growth phase.
• While billable sample volume decreased by 11%, the significant increase in ASP and revenue suggests a strategic shift towards higher-value tests and a focus on reimbursement, which is a common strategy in the diagnostics industry.
• Companies like Exact Sciences (EXAS) and Guardant Health (GH) also focus on innovative diagnostic testing, but DermTech's focus on non-invasive skin genomics is a unique approach. DermTech's revenue growth of 31% is comparable to some of the growth rates seen in the broader diagnostics sector, but the company is still in an earlier stage of commercialization.

Stakeholder Impact

• Shareholders may view the improved financial results and extended cash runway positively.
• Employees may be impacted by the restructuring actions and cost reductions.
• Customers and patients may benefit from the company's focus on improving the standard of care for evaluating melanoma.
• Suppliers and creditors may be impacted by the company's efforts to reduce costs and improve financial stability.

Next Steps

• The company will continue to focus on increasing average selling price and revenue growth in 2024.
• DermTech will continue to emphasize operating efficiencies and resource allocation.
• The company will host a conference call to discuss the results on February 29, 2024.

Key Dates

Keywords

DermTech, Melanoma Test, Precision Dermatology, Genomics, Financial Results, Revenue Growth, Cost Reduction, Gross Margin, Operating Expenses, Cash Runway